CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
ferumoxytoldrug
Likely dose
ferumoxytol 510 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01148745
NCT01148745Phase 4Completed
CompareCT.gov

Iron Indices and Intravenous Ferumoxytol: Time to Steady State

Dialysis Clinic, Inc.·interventional·Posted Jun 22, 2010·Updated Mar 30, 2012

In Brief

A Phase 4 clinical trial evaluating ferumoxytol for Iron Deficiency Anemia. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the time point of transferrin saturation (TSAT) and ferritin stabilization after a thirteen-treatment period following a ferumoxytol load, as well as to determine the point at which serum ferritin and TSAT concentrations can be checked in iron deficiency anemia (IDA) hemodialysis patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Deficiency Anemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 22, 2010
Enrollment StartMar 1, 2010
Primary CompletionApr 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.0 years ago

Interventions

ferumoxytoldrug

510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)